Targeting peptides provide a small, chemically flexible platform connecting small-molecule tracers and bulky antibodies for nuclear medicine. This small size (sub-kDa) allows rapid extravasation and deep tissue diffusion. In addition, the peptide backbone is sufficiently modular to support grafting of chelators, radiohalogens or prosthetic groups without hindering receptor binding; they can therefore provide high-contrast images with therapeutically relevant radiation doses while imposing a limited burden on the patient. Short half-life in circulation and susceptibility to proteolysis have to be countered by backbone design and linker chemistry able to retain the radiolabel intact to the target.
Schematic representation of the structure of target-specific peptide-based radiopharmaceuticals. 1,5
Peptides bridge the gap between bulky, long-circulating antibodies and small, non-specific small molecules: they can be labelled within hours, diffuse into tumors within minutes and clear from normal organs rapidly enough to use isotopes with half-lives as short as minutes or as long as days. Their solid-phase syntheses tolerate orthogonal chemistry, enabling late-stage introduction of macrocyclic chelators or click handles that survive radiolabelling under mild aqueous conditions. The ability to adapt quickly reduces the time from laboratory to patient care while enabling swift clinical redirection for newly discovered receptors.
The half-life of the commonly used PET isotopes is only minutes, so a peptide must find and internalize its membrane target before its second pass through circulation in order for the signal to be detected before the radionuclide has decayed sufficiently to reduce the contrast (signal to noise). This requires fast on-rates and little steric hindrance for internalization to occur rapidly. It also means the tracer cannot bind to plasma proteins, which would otherwise form a reservoir of tracer in circulation that is not available for binding. To be certain in diagnosis, a tracer must accumulate to concentrations that are orders of magnitude above the radioactivity in surrounding tissues. This means peptides must have affinity in the nanomolar range and that the unbound fraction must be cleared rapidly by renal or hepatobiliary pathways and there should be no metabolites that can redistribute the isotope into non-targeted organs. This can be achieved by cyclization of the peptide backbone, introduction of D-amino acids, and insertion of hydrophilic spacers, all of which help to minimize off-target binding and facilitate urinary excretion of remaining activity.
Since they are below the kidney filtration cutoff and have small hydrodynamic radii, peptides leak out of the blood vessels and diffuse well into the tissue, making them an ideal delivery method for solid tumors, in particular fibrotic or hypoxic lesions, which are largely inaccessible to larger vectors. Because they are also low immunogenic, peptides can be repeatedly administered at short intervals, allowing monitoring of the therapeutic response without the development of anti-drug antibodies. Chelators like DOTA or NOTA can be introduced at a known position in the peptide chain via solid-phase synthesis, without interfering with the receptor binding functionality of the peptide, and form a strong complex with the radiometal. Linkers of different lengths and hydrophobicities can be added to the chelator to fine-tune the lipophilicity and renal retention of the peptide, allowing the same peptide backbone to be used for different isotopes with different coordination properties. This flexible, or "plug-and-play" nature of the peptide delivery system allows a much shorter lead time and regulatory load than the development of new biological vectors for each nuclide.
Table 1 Peptide attributes aligned with radiopharmaceutical demands.
| Attribute | Imaging benefit | Therapy benefit | Engineering tactic |
| <3 kDa | Fast clearance → low background | Rapid tumor penetration | Keep sequence minimal |
| Fast on-rate | High contrast at 5–15 min | Dose delivery before decay | Pre-organised binding loop |
| Moderate off-rate | Washout from normal tissue | Re-binding during longer decay | Tune linker rigidity |
| Single tyrosine or lysine | Clean radiolabelling site | Stoichiometric 1:1 complex | Introduce away from epitope |
| Protease capping | Intact tracer in blood | Intact tracer in tumour | N-acetylation, D-amino acid |
| Click-ready handle | Late-stage 68Ga or 18F incorporation | Same handle for 177Lu or 225Ac | Azide/alkyne on side-chain |
Due to their pharmacokinetic flexibility reminiscent of small molecules, but with molecular recognition capabilities approaching those of biologics, targeting peptides are well-suited platforms for the delivery of radioactive cargo. With an intact molecule often having a molecular weight in the sub-kilodalton range, the ability of peptides to extravasate quickly and penetrate deep into tissues is not atypical. In addition, the modular nature of the peptide backbone allows for the incorporation of chelators or radiohalogens, without necessarily disrupting receptor binding. As a result, this leads to the dual advantage of both high-contrast images as well as therapeutic doses of radiation while keeping patient exposure as low as reasonably achievable, a balance that is difficult to attain with larger antibodies or non-specific small molecules.
Enhanced imaging contrast results from the ability of sub-3 kDa peptides to pass through fenestrated tumor vasculature during the first pass of circulation and to clear from receptor-negative tissues prior to the build-up of background activity. The resulting high target-to-non-target ratio can be visualized within minutes, so that late-phase images can be acquired when blood pooling is minimal. Low background signal is also helped by primarily renal excretion; peptides without lipophilic patches are not subject to hepatobiliary recirculation, so that radioactivity is rapidly excreted in the urine instead of remaining in the intestines or reticulo-endothelial system.
Affinity and selectivity can be receptor-selective and engineered with the incorporation of non-natural residues or constrained scaffolds that bind to tumor-associated pockets with nanomolar affinity and discriminate against homologous pockets on normal cells. Conformational restriction such as cyclisation, stapling or N-methylation of the peptide backbone can pre-organize the bioactive conformation, which can improve selectivity without increasing molecular size. Off-target accumulation can be minimized by siting the chelator away from the binding epitope and optimizing the overall charge, to avoid electrostatic binding to serum albumin or unspecific uptake by proximal tubule cells, two major off-targets that otherwise can cause both image blurring and nephrotoxicity.
The inherent flexibility of peptide–chelators allows the same peptide backbone to be "switched" from 68Ga or 18F for same-day PET imaging to 177Lu, 90Y or 225Ac for multi-day therapy without needing to re-optimize affinity for the target receptor. Macrocyclic or acyclic chelators may be introduced at lysine, cysteine or N-terminal positions in the course of solid-phase synthesis, and thus enable kit-type radiolabelling at radiopharmacies. Additional advantages of modular design include the ability to insert spacers to "shield" the isotope from the binding surface, add albumin-binding motifs to extend the half-life, or create multivalent arrays that increase avidity for therapy while maintaining rapid clearance for diagnosis—all through the same synthetic route.
Radiotracers are affected by an apparent trade-off between biological lability and pharmacokinetic impermanence: plasma half-lives that are too short and high protease susceptibility preclude tumor saturation (delivered dose decay before accumulation reaches a maximum), while unimpaired clearance and small molecule transit to the renal proximal tubules risk nephrotoxicity of the residualizing component of activity. The confluence of these liabilities requires that peptide stability, radionuclide cage and excretion route be simultaneously optimized as any isolated intervention is quickly found to result in invisible images or unacceptable off-organ doses.
The structural components of a peptide-based positron emission tomography (PET) radiopharmaceuticals. 2,5
Clearance-retention trade-offs have long been a mainstay of peptide radiochemistry: modifications that lengthen plasma residence time such as albumin-binding motifs or D-amino acid stitching have consistently been shown to improve tumor uptake at the cost of increasing blood-pool background and marrow radiation dose, while, conversely, ultra-rapid clearance of a tracer may maintain excellent contrast but sacrifice lesion uptake when the targeted receptor is not overexpressed. The half-life of the isotope of choice therefore sets the upper limit of the acceptable residence time; a 110-minute emitter, for example, must be attached to molecules that reach maximum target-to-organ ratios in a matter of minutes, whereas a 6-day therapeutic isotope can accommodate slower kinetics in exchange for a higher whole-body radiation dose. Effects on image interpretation are most significant if early frames are recorded after the onset of this metabolite washout: metabolites that have accumulated in renal calyces or liver sinusoids at that point are responsible for persistent hot spots that conceal lesions and make quantitation more difficult.
Serum aminopeptidases and renal brush-border enzymes usually cleave after a basic or aromatic residue. These radiolabelled cleavage products cause background uptake. Blocking exopeptidase attack with cyclisation, D-amino acid substitution, or N-methylation is possible, but each of these must be individually validated to ensure it does not diminish receptor affinity. In-silico protease mapping followed by iterative library screening during lead optimization is now standard. Accumulation of any cleavage products bearing the radiometal within the liver or gut, can obscure any tumor signal. Linkers that self-immolate only following lysosomal proteolysis trap the radiometal intracellularly while the unbound parent peptide is rapidly cleared by filtration. This retention-by-design approach has been shown to lower background signal without prolonging systemic half-life.
The same rapid renal clearance that minimizes blood background tends to concentrate radioactivity in the renal cortex, leading to nephrotoxicity at therapeutic activities. Positively charged peptides or those containing lysine residues are particularly subject to megalin/cubilin mediated reabsorption. Competitive tubular reuptake block by anionic or neutral residues distal to the chelator moiety or co-infusion of amino acid solutions is possible without perturbing tumor uptake. Albumin-binding tags or fatty-acid appendages will increase circulation time and divert clearance from renal to hepatic pathways at the expense of increased liver exposure. In an alternative approach, click-to-polymer methods allow the peptide to self-assemble into nanoparticles only after reaching the tumor and sequester the radiometal once inside the tumor while the parent peptide continues to be cleared by the kidneys. These approaches illustrate how judicious chemistry can convert a liability into a safety feature.
Successful peptides are compromises: they must withstand proteases in blood, rapidly reach tumor receptors, and quickly disintegrate if the peptide-target complex is inappropriately formed. There are three levers to achieve these conflicting goals: stabilize the peptide backbone without substantially increasing molecular size, optimize affinity such that capture by tumors is fast but reversible, and carefully position the chelator so that it does not block the binding epitope and does not fall apart under isotope decay. Each lever is adjusted iteratively, guided more by pharmacokinetic read-outs than by affinity alone.
Cyclisation and backbone modification transform the linear precursor into a small, conformationally constrained loop that is aminopeptidase and serum protease resistant. Head-to-tail lactam or disulfide bridges decrease backbone mobility and pre-organize bound and unbound conformations such that receptor engagement is fast but enzymatic cleavage is sterically impeded. If the epitope can accommodate further constraint, double-click staples or hydrocarbon tethers are introduced between residues on the opposite face of the binding interface; linker length is matched to helical pitch such that the staple does not perturb the recognition surface but still occludes endoprotease access. Protease resistance strategies further complement cyclisation by shielding the vulnerabilities that remain. N-methylation of selected amide bonds, D-amino acid substitution at non-contact sites and C-terminal amidation each reduce kcat for aminopeptidases without adding to overall mass or lipophilicity. Insertion of ψ-CH2-NH or β-amino acid linkers provide an isosteric backbone which proteases cannot recognize, but which preserve the hydrogen-bond directionality needed for receptor complementarity. The overall result is a peptide scaffold that is still present in useful quantity by the first tens of minutes post-injection—the critical window for most generator-produced positron emitters—while still presenting the native epitope to the surface of the tumor cell.
Efforts to avoid saturation focus on the notion of an affinity ceiling: KDs driven into the picomolar range produce an "affinity sink" at the tumor periphery that acts as a barrier to deeper diffusion, thus channeling dose into the perivascular spaces. Developers therefore back off from further maturation at the point where single-digit nanomolar affinity is achieved, recognizing that off-rates in the minute range will allow each peptide molecule to interrogate multiple cells per circulation cycle, thus spreading the radionuclide load more evenly across the lesion. Tuning kinetics and specificity is therefore accomplished by grafting only the hotspot residues onto a minimal cyclic template; flanking residues are trimmed to speed up diffusion, while charged or PEGylated appendages are added sparingly to optimize residence time. Multimerization is used judiciously—dimers, for example, increase avidity but also molecular weight; the spacing between binding modules is set close to the average inter-receptor distance so that simultaneous engagement is geometrically possible on tumor cells but unlikely on normal tissue, resulting in selectivity without the extended plasma half-life that would increase marrow dose.
Minimization of interference with binding can be accomplished by placing stiff, hydrophilic spacers that push the chelator away from the pharmacophore. Short oligo-ethylene glycol or sulfated carbohydrate spacers keep the elements apart without introducing lipophilicity that might redirect the tracer back to hepatocytes; the spacer length is calculated in silico to position the metal complex outside the receptor pocket but still within the grasp of coordinating side-chains. Resistance to structural disruption by radioactive decay requires chelators that are stable against trans-metalation once the complex is exposed to the recoil energy of β- or α-emission. Macrocyclic cages such as DOTA or cross-bridged derivatives are often favored over acyclic ligands because they possess both thermodynamic and kinetic inertness in vivo; the chelator itself can be further locked into place by sterically protecting the coordination sphere from challenge by competing serum cations. For peptides intended for therapeutic use, the linker is also designed to be cleavable only once internalized. This causes any unbound conjugate to be of sufficiently small size for rapid renal filtration while the receptor-bound payload is held inside the cell. This built-in safety feature also simultaneously reduces kidney dose and enhances tumor residence.
Table 2 Design Levers for Peptide Radiotracers
| Design Element | Traditional Risk | Engineering Solution | Clinical Pay-off |
| Backbone flexibility | Proteolysis | Cyclisation + N-methylation | Longer imaging window |
| Ultra-high affinity | Off-tissue retention | pH-sensitive spacer | Lower background dose |
| Bulky chelator | Binding interference | Flexible/rigid hinge | Preserved affinity |
| Spacer rigidity | Radiolytic cleavage | Self-immolative spacer | Intracellular retention |
| Multivalency | Increased MW | Compact 3–5 nm spacing | Higher avidity, same clearance |
The choice of a peptide as the delivery vector for a radionuclide is a matter less of fashion than of biological constraint: the molecule must get to its binding site more rapidly than the isotope decays, the site must be extracellular, and the number of receptor copies must be high enough for a nanomolar ligand to out-compete renal clearance. When all three are in place, peptides can do better than antibodies in speed, and outstrip small molecules in specificity; violate any one, and the same ligand can become an expensive way to irradiate kidneys and bladder.
Peptides are at home in the extracellular space where their accessible targets reside. G-protein-coupled receptors, integrins, somatostatin receptors and bombesin-family GRP receptors all have large, solvent-exposed pockets that can be targeted without crossing a membrane; the ligand need only withstand the relatively short transit from capillary to cell surface. Because diffusion distances are in micrometers rather than millimeters, a 2–3 kDa cyclic peptide can fill >80 % of available sites in the first ten minutes, a time-scale that matches the half-life of generator-produced positron emitters and results in PET images with high tumor-to-background contrast. High receptor density systems further tip the balance in favor of peptides: when the antigen is expressed at tens of thousands of copies per cell, even a moderate-affinity ligand can pull down a diagnostically useful fraction of the injected activity during a single capillary pass. Neuro-endocrine tumors, prostate cancer lesions over-expressing GRP receptors and certain breast cancer sub-types fall into this category; here the peptide delivers a signal amplification that rivals antibody-based tracers while clearing from blood fast enough to permit same-day scanning and outpatient therapy. Finally, the chemical modularity of peptides allows rapid re-tooling when receptor isoforms shift; a single solid-phase synthesis can swap tyrosine for DOTA-conjugated lysine or insert an albumin-binding tail to extend half-life for longer-lived therapeutic isotopes, a flexibility that shortens the path from bench to bedside when new biomarkers emerge.
Poorly accessible targets quickly reveal peptides' Achilles heel. Antigens hidden below endothelial tight junctions, secluded in hypoxic cores behind dense collagen, or on the luminal side of the blood–brain barrier are invisible to circulating peptides that depend on fenestrated vasculature for extravasation. In these environments, smaller, more lipophilic small molecules, or larger antibodies engineered with tumor-penetrating peptides, may achieve deeper distribution because they either diffuse trans-cellularly, or use Fc-mediated transcytosis. Similarly, extremely low receptor expression is a basic mismatch: when the antigen copy number falls below a few thousand per cell, the likelihood that a nanomolar peptide will find and bind its partner during a sub-minute transit is vanishingly small. The same dose that provides crisp images in a high-density lesion is lost in statistical noise, forcing investigators to inject more activity and increase renal and red-marrow dose without proportional therapeutic gain. Here, high-affinity antibody fragments, bispecific vectors or nanoparticles carrying multiple copies of the ligand can provide the avidity boost needed to extract signal from background. Finally, if the intended target is an intracellular oncoprotein, the peptide's limited cell permeability is a deal-breaker; stapled or lipidated variants may enter cells in vitro, but in vivo they are typically intercepted by liver or cleared via bile, making oligonucleotide aptamers, antibody–drug conjugates, or small-molecule inhibitors more logical choices. In short, peptides excel where speed, modularity and extracellular access align; where geometry, density or topology diverge from these ideals, alternative scaffolds should be prioritized early rather than after costly clinical mis-steps.
Radiopharmaceutical targeting places unique demands on peptide design that differ fundamentally from conventional drug delivery. Short biological half-life, rapid clearance, radiolabel-induced stress, and strict signal-to-background requirements mean that even minor design mismatches can significantly compromise performance. Our targeting peptide services are structured specifically to address these constraints through radiochemistry-aware design and feasibility-driven development. Rather than adapting generic targeting peptides for radiopharmaceutical use, we develop peptide architectures with imaging and radionuclide delivery requirements built in from the outset.
Radiochemistry-Aware Sequence Design: Radiolabeling can impose chemical and structural stress on targeting peptides, particularly when chelators or prosthetic groups are introduced near functionally critical regions. Our radiochemistry-aware sequence design approach explicitly accounts for how labeling chemistry influences peptide conformation, stability, and target binding. We identify labeling-tolerant regions within the peptide scaffold and avoid sequence motifs that are prone to radiolysis or chemical modification during labeling. This minimizes disruption to receptor binding and reduces the formation of unstable radiolabeled species that contribute to background signal or rapid degradation. By designing peptides with radiolabel compatibility in mind, we help preserve targeting performance in the final radiopharmaceutical construct rather than only in the unlabeled precursor.
Performance-Driven Optimization: In radiopharmaceutical development, optimal performance is defined by functional outcomes—such as tumor-to-background ratio and temporal signal dynamics—rather than binding affinity alone. Our optimization strategy therefore focuses on performance-driven parameters, including clearance kinetics, in vivo stability, and retention at the target site. Peptide sequences are tuned to balance rapid tissue penetration with sufficient target engagement, avoiding designs that either clear too quickly to generate usable signal or persist excessively in non-target tissues. This application-specific optimization ensures that peptide behavior aligns with the intended imaging or radionuclide delivery window.
Feasibility-Driven Development: Not all biological targets are equally suited for peptide-based radiopharmaceuticals. Our development process begins with a feasibility-driven assessment of target accessibility, expression profile, and compatibility with peptide kinetics. This early evaluation helps identify whether a given target is likely to support rapid, specific uptake with acceptable background clearance—key determinants of radiopharmaceutical success. When feasibility risks are identified, design strategies are adjusted accordingly or alternative approaches are recommended before significant resources are committed.
Early Performance Validation: Early validation is critical in radiopharmaceutical development, where late-stage failures are costly and difficult to recover from. We integrate early performance testing to assess peptide stability, labeling robustness, and targeting behavior under conditions that closely reflect intended use. These early datasets inform iterative refinement of peptide design, enabling data-driven optimization rather than reactive troubleshooting. By validating performance early, we help ensure that candidate peptides entering advanced development stages are aligned with real-world radiopharmaceutical requirements.
If your radiopharmaceutical program is limited by low target uptake, high background signal, or instability after radiolabeling, an early technical discussion can help identify whether peptide design or target selection is the underlying issue. Discuss your radiopharmaceutical targeting challenge with our team to evaluate feasibility, assess design risks, and define a peptide optimization strategy tailored to your imaging or radionuclide delivery goals.
References
